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Abstract
The incidence of leukemia is higher in Down syndrome children than that in the
general population, while the risk of solid tumors is significantly reduced in Down
syndrome. Recent studies utilizing mouse models have shown that distinct mecha‐
nisms caused by the elevated dosage of multiple genes is implicated in the protection
from tumor progression depending on the type of solid neoplasm. In contrast,
increased incidence of mutation in the several specific genes is reported as a cause of
the onset of leukemias. Especially, acquired mutations in the GATA1 gene are
associated with leukemogenesis of megakaryoblastic leukemia (AMKL) and transient
myeloproliferative disorder (TMD) related to Down syndrome. The mutations are
clustered in the region corresponding to the N-terminal domain of GATA1 and result
in the production of the short form of GATA1 (GATA1-S), which utilizes Met84 as an
alternative translation initiation codon. Efforts producing mouse models of Down
TMD and AMKL have been undertaken, as these models seem to provide important
insights into the pathogenesis of multistep leukemogenesis. Concomitantly, the
function of GATA1 has been examined extensively, and the analyses present a
prototype for the study of lineage-restricted transcription factors that play an essential
role for the differentiation, proliferation, and apoptosis of erythroid cells, megakar‐
yocytes, mast cells, and eosinophils. In this chapter, we will summarize recent
progress in the studies of leukemias that occur in Down syndrome, especially in
relation to GATA1 mutations.
Keywords: Acute megakaryoblastic leukemia, Acute lymphoblastic leukemia, Tran‐
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1. Introduction
The risk of solid tumors is significantly reduced in Down syndrome (DS) patients compared
with the general population [1-3]. Studies utilizing mouse models have shown that distinct
mechanisms caused by the elevated dosage of multiple genes are implicated in the protection
from tumor progression depending on the type of solid neoplasm. In contrast, DS children
have an increased risk of developing leukemias. Specifically, acute megakaryoblastic leukemia
(AMKL) and acute lymphoblastic leukemia (ALL) are approximately 500 and 10-50 times more
prevalent in children with DS compared to healthy controls, respectively [4-6].
Recent analyses have uncovered that a distinct pattern of acquired genetic mutations is
implicated in the leukemogenesis restricted to DS children. In particular, acquired mutations
in the GATA1 gene are associated with leukemogenesis of DS-associated AMKL and transient
myeloproliferative disorder (TMD), a preleukemic disorder unique to neonates with DS. The
mutations are clustered in the region corresponding to the N-terminal domain of GATA1 and
result in the production of a short form of GATA1 (GATA1-S), which utilizes Met84 as an
alternative translation initiation codon. The function of GATA1 has been studied extensively,
and the analyses present a prototype for the study of lineage-restricted transcription factors
that play essential roles in the differentiation, proliferation, and apoptosis of erythroid cells,
megakaryocytes, mast cells, and eosinophils. In this chapter, we summarize recent progress
in the research on leukemias related to DS. Research of mouse models of DS TMD and AMKL
has been undertaken, as these models seem to provide important insights into the pathogenesis
of multistep leukemogenesis.
2. Unique features of leukemias associated with Down syndrome
There are substantial biological differences between the leukemias that occur in DS and non-
DS children. It becomes increasingly clear that molecular mechanisms based on trisomy 21
affect not only the high incidence of leukemias but also the characteristic features of DS-
associated leukemias.
2.1. DS-associated AMKL
Approximately 5-30% of DS babies are born with a leukocytosis with an erythroid-megakar‐
yocytic immunophenotype. The severity of the clinical course varies with each case, from
asymptomatic cases likely to have been considered peaceful births to severe cases resulting in
critical injuries with blast cell infiltration of the organs. In severe cases, death from multiorgan
failure or hepatic fibrosis is possible, requiring intensive care for the babies. Except for the most
severe cases, symptoms usually resolve naturally (Figure 1). Therefore, DS-related leukocy‐
tosis is referred to as transient abnormal myelopoiesis (TAM) or transient myeloproliferative
disorder (TMD). Patients suffering from TAM spontaneously achieve complete remission by
6 months of age. While the mechanisms of this spontaneous remission are still under investi‐
gation, one recent report showed that type I interferon signaling activated in bone marrow
appears to attenuate the hyper-proliferation of megakaryocytes caused by the GATA1-S
mutation [7].
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Figure 1. Multistep leukemogenesis of DS-associated AMKL. Megakaryocytic progenitors that have acquired vari‐
ous types of GATA1 gene mutations eventually converge to GATA1-S, which develops TMD in DS fetus. The hyper‐
proliferation phenotype of TAM blasts is canceled after birth. However, unknown genetic alterations transform the
residual blasts to genuine leukemia.
After several years of asymptomatic periods, approximately 20% of DS children with a history
of TAM develop genuine AMKL requiring intensive chemotherapy (Figure 1). It has been
hypothesized that every DS child first diagnosed with AMKL has a history of asymptomatic
TAM at birth. As a result, the incidence of AMKL in DS children is more than 500 times higher
than in children without trisomy 21. Thus, this characteristic feature of DS-associated AMKL
represents a potentially tractable model of multistep leukemogenesis. Chemotherapy in
children with DS-associated AMKL shows a high cure rate. Therefore, the outcome of DS
children with AMKL is statistically better than that of AMKL patents without trisomy 21 [8],
probably due to the unique biological characteristics of blast cells. The molecular mechanisms
of these remarkable differences remain as yet unknown.
In 2001, it was discovered that somatic mutations on the GATA1 gene are frequently found in
AMKL cases occurring in DS children [9]. Supporting evidence has appeared following the
release of a paper describing the GATA1 gene mutations found in TAM and DS-associated
AMKL cases (Figure 1). Of note, the mutations are clustered in the region corresponding to
the N-terminal domain of GATA1 and result in the production of the short form of GATA1
(GATA1-S) utilizing Met84 as an alternative translation initiation codon (Figure 1). A clinical
study utilizing Guthrie blood shows that the GATA1 gene mutation is found in the 3.8% of DS
babies who are not diagnosed with TAM at their birth [10]. In some non-DS AMKL cases with
the GATA1 gene mutation, leukemic blasts originate from the cells that have somatically
acquired trisomy 21 during myeloid development [11]. Similar cases are also observed in cells
carrying trisomy 21 in mosaic models [12], suggesting that a cell-autonomous program
provoked by the GATA1 mutation and trisomy 21 contributes to the onset of TAM. Relatively
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few cases of AMKL harboring mutations in the GATA1 gene exist in the absence of trisomy 21
[13, 14]. Therefore, the pathogenesis of TAM seems to be closely associated with GATA1
dysfunction in combination with the impact provided by the extra chromosome 21. One of the
important remaining questions is how DS children frequently acquire the GATA1 gene
mutation.
Sequential surveys of cases of TAM-AMKL have revealed that the type of GATA1 gene
mutations detected in AMKL blasts is frequently identical to that found in TAM blasts in each
individual case, suggesting that AMKL develops in the TAM blasts. It seems plausible that
TAM blasts survive during an asymptomatic period and some of the blasts receive additional
hits and become genuine leukemic stem cell (Figure 1). Indeed, exome sequencings of TAM
and AMKL blasts have revealed that the TAM blasts from one case have a singular GATA1
gene mutation, while multiple mutations in the genes encoding for the cohesin components
and epigenetic regulators are accumulated in the AMKL blasts in addition to the original
mutation in the GATA1 gene [15].
2.2. DS-associated ALL
Acute lymphoblastic leukemia (ALL) is one of the most common malignant diseases in
children, and DS children have a higher incidence of this disease than non-DS children. In
contrast to the DS-associated AMKL cases, the prognosis of DS-associated ALL is worse than
ALL without DS. This may be because DS children are prone to suffer from significant toxicity
of chemotherapy, as DS-associated ALL blasts retain high resistance against conventional
chemotherapy regimens [16-18]. Intrachromosomal amplification of chromosome 21 (iAMP21)
is also recurrently found in pediatric B cell leukemia, and this finding is considered to be an
adverse prognostic factor [19, 20]. It has been demonstrated that target genes of the polycom
repressor complex 2 (PRC2) are upregulated in both DS-associated ALL and ALL with iAMP21
[21], indicating that an epigenetic regulation provoked by trisomy 21 is a key mediator of the
pathogenesis of this type of leukemia.
Mutations in the developmental genes for B-cell and T-cell lineages are often implicated in the
pathogenesis of ALL, irrespective of the presence of Down syndrome. In addition to these
genes, the incidence of mutations on genes involving the JAK/STAT pathway and RAS
signaling have been found to be increased in DS-associated ALL [22-24], suggesting that
molecular changes provided by these mutations may be the reason for the poor survival rate
in children with DS-associated ALL.
3. Hematopoiesis in Down syndrome
It has been shown that hematopoietic homeostasis is significantly disturbed in DS fetus [25].
For example, frequencies of hematopoietic stem cells and megakaryocyte-erythroid progeni‐
tors are markedly increased showing high clonogenic characteristics, whereas that of granu‐
locyte-macrophage progenitors is reduced [25-27]. In addition, committed pre-proB lymphoid
and proB lymphoid progenitors are markedly reduced [25, 26]. This hematological abnormal‐
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ity may be a predominant cause of AMKL and ALL in DS babies. While the hematological
abnormalities observed in newborns and infants with DS vary case by case, the following
abnormalities are often observed: macrocytosis, neutrophilia, thrombocytopenia, and polycy‐
themia [28-30]. In contrast to the high risk of leukemias in the pediatric period, leukemias are
no longer a common cause of death in adults with DS [31]. Instead, macrocytosis and leuco‐
penia are often observed in adult DS cases, leading to the early onset of myelodysplastic
syndrome and bone marrow failure [32].
Strictly speaking, DS is defined by the possession of three copies of DS critical region (DSCR)
of human chromosome 21 instead of two. However, the expression of genes located on
chromosome 21 or the DSCR in DS patients is not always increased to 1.5-fold that of healthy
controls. Depending on the expression levels, genes on human chromosome 21 or DSCR are
divided into three categories: i) overexpressed genes, ii) genes expressed comparable to those
in diploid healthy controls, and iii) genes whose levels are varied in individuals with DS. It
has been reported that the frequency of genes overexpressed (type i) in B lymphocytes of DS
patients is 22-39%, and the set of overexpressed genes in B lymphocytes differs from that found
in fibroblasts [33, 34]. Therefore, it seems likely that the genes that proportionally increased
due to the gene-dosage effect contribute to the common characteristic feature of DS, while the
genes whose expression is varied in individuals determine the conditions of the individuals.
In addition, microRNAs may be involved in the determination of DS disease types [35].
Expressional imbalances of chromosome 21-derived microRNAs may contribute to the
diversified symptoms in DS patients.
To investigate the contribution of trisomy 21, three groups have independently established iPS
(induced pluripotent stem) cells originated from DS patients and analyzed the hematopoietic
differentiation. When iPS cells are cultured under the condition of primitive hematopoiesis
(the first phase of hematopoiesis in yolk sacs), erythropoiesis is enhanced and myelopoiesis is
reduced, while megakaryocytes are normally produced [36]. In contrast, when cultured under
the condition of preferentially differentiating into fetal liver–derived definitive hematopoietic
cells (the second phase of hematopoiesis in the fetal liver), iPS cells with trisomy 21 show
increased multilineage colony-forming potential, and the number of cells with a myeloid and
erythroid bipotential phenotype is increased [37]. However, trisomic iPS cells show no
difference from isomic iPS cells when they are cultured in a condition suitable to generate
erythroblast co-expressing embryonic and fetal globin genes [38]. Thus, the iPS studies suggest
that the influence of one extra chromosome 21 to hematopoiesis is altered depending on the
hematopoietic microenvironment.
Hematopoietic phenotypes have been examined in multiple lines of DS-model mice. Tc1 mice
harbor an aneuploidy, carrying freely segregating human chromosome 21. The Tc1 mice show
macrocytic anemia and an increased number of megakaryocytes with extramedullary hema‐
topoiesis in the elderly. On the contrary, significant changes in frequencies of megakaryocytes,
erythroid, and myeloid progenitors were not observed in the fetal liver [39]. Ts16 mice were
generated by crossing mice with Robertsonian translocation Rb (14;16) and Rb (9;16), resulting
in animals trisomic for mouse chromosome 16 (synthetic of human chromosome 21). Ts16 mice
show increased erythropoiesis and reduced myelopoiesis during the embryonic period [40],
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but defects in hematopoiesis after the neonatal and infantile periods are uncertain, as Ts16
mice do not survive the postnatal period.
Ts65Dn, Tc1Cje, and Ts1Rh mice have been established as lines of euploid DS-model mice
bearing a segmented region of mouse chromosome 16 containing 104, 81, and 33 genes,
respectively. The Ts65Dn mice suffer from macrocytic anemia with defects of stem cell function
and progressive myeloproliferative diseases [41]. In contrast, erythropoiesis is disturbed in
Tc1Cje mice, but the mice never develop thrombocytosis or myeloproliferative diseases [42].
Hematopoietic analyses have been performed in Ts1Rhr mice, which are trisomic for the mouse
equivalent of the hypothetical human DSCR; these mice show anemia and thrombocytosis in
adulthood. Bone marrow cells of the mice preferentially differentiate toward the granulo-
monocyte pathway, while the number of B cell progenitors is reduced [21, 43]. During the
embryonic stage, hematological abnormalities are not found in Ts1Rhr mice, except for a
significant increase in the hematopoietic stem cell population. Although each line of DS-model
mice shows partially overlapping hematological phenotypes with those observed in patients
with DS, none of the mice develop leukemia or acquire the Gata1 gene mutation.
4. GATA1 gene mutation in TAM and DS-associated AMKL
GATA1 is a founding member of the GATA family transcription factors that recognize
consensus GATA binding motif. In mammals, the hematopoietic GATA subfamily is com‐
posed of GATA1, GATA2, and GATA3, which are expressed in erythroid and megakaryocytic
cells, hematopoietic stem and progenitor cells, and T cells, respectively [44]. The expressions
of GATA1 and GATA2 are partially overlapping, and these two GATA factors regulate the
expression of each other. In early erythroid-megakaryocytic progenitors, GATA2 initiates
GATA1 gene expression, while GATA1 downregulates GATA2 gene expression together with
activation of its own gene expression [45]. We refer to this network regulation of GATA2 and
GATA1 as GATA factor switching [45]. In addition, GATA1 and GATA2 share, at least in part,
their target genes [46]. Consequently, GATA1 and GATA2 competitively or redundantly work
for the expressions of their target genes dependent on the gene properties. Therefore, the
functional balance of GATA1 and GATA2 is important for the maintenance of hematopoietic
homeostasis.
The GATA1 gene is composed of one untranslated first exon and five translated exons (Figure
2). The translation initiation codon located in the second exon is usually utilized to produce
the full length of GATA1. Interestingly, an alternative splicing variant caused by the skipping
of the second exon has been noticed in healthy humans, producing a short form of GATA1
protein lacking amino (N)-terminus 83 amino acids, which is identical to GATA1-S, utilizing
an alternative translation initiation codon located in the third exon (Figure 2) [47]. In the case
of mice, a short isoform of GATA1, a mouse ortholog of human GATA1-S, is also generated
by the use of an alternative translation initiation codon in a single mRNA shared with the full-
length of GATA1 [48]. Thus, two forms of GATA1 protein, GATA1 and GATA1-S, are both
present simultaneously in healthy humans and mice, although the physiological roles of the
GATA1-S isoform remain to be clarified.
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Figure 2. GATA1 gene construction and splicing variants.GATA1 gene is composed of an untranslated first exon and
five translated exons. Full-length GATA1 is produced utilizing a translation initiation codon located in the second exon
(upper panels). On the other hand, the GATA1-S variant is produced based on an alternative splicing variant, skipping
the second exon and utilizing a methionine codon AUG corresponding to the 84th amino acid of full length of GATA1
(lower panels). Consequently, GATA1-S lacks the N-terminus 83 amino acids.
The GATA1 mutations in TAM cases are clustered in the second exon of the GATA1 gene,
leading to the production of frame-shift misincorporation with the premature translation
termination codon. Alternatively, mutations inducing pathological skipping of the second
exon have also been reported [49]. Thus, the GATA1-S, but not the full-length GATA1, is
exclusively produced in the TAM/AMKL blasts, indicating that aberrant function of GATA1-
S in the absence of the expression of the full-length GATA1, rather than simple loss-of-GATA1-
function, is involved in the onset of TAM.
GATA1 has four functional domains, two transactivation domains in the N- and carboxy (C)-
terminal regions and two zinc-finger domains in the middle of body, which are important for
the interaction with DNA and multiple cofactors (Figure 3A). Conventional cell-based
luciferase reporter assays show that transactivation activity of GATA1-S is reduced into 30%
of the full-length of GATA1, which is supported by the function of the C-terminal domain [50].
Functional analyses in mice in vivo indicate that the N-terminal and C-terminal transactivation
domains differentially and cooperatively contribute to gene expression, depending on the
property of GATA1 target genes. GATA1 target genes can be divided into three categories: the
first group of genes requires only the N-terminal domain, the second group of genes requires
only the C-terminal domain, and the third group of genes requires both domains [50]. The
expression of only GATA1-S leads to the imbalance of GATA1 target gene expression, which
may be implicated in the pathogenesis of TAM.
Importantly, provability of transformation into AMKL inversely correlates with the expression
level of GATA1-S, and the latter is heavily dependent on the type of mutations in GATA1 gene
[48]. In the case of the mutations producing high amounts of GATA1-S, the incidence of AMKL
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is relatively low. However, such cases frequently suffer from high blast counts in the peripheral
blood and require chemotherapy to prevent organ infiltration with the blasts. In contrast,
patients with low amounts of GATA1-S frequently develop AMKL. Thus, the expression levels
of GATA1-S influence leukemia progression and disease status.
Recently, two types of internally deleted (ID)-type GATA1 proteins were reported as a cause
of TAM (Figure 3B) [51]. In the blasts of these cases, aberrant transcripts are produced due to
splicing mutations in the GATA1, and, consequently, GATA1 proteins lacking amino acid
residues 77-119 or 74-88 are produced. The N-terminal end of GATA1 is retained in the newly
identified ID-type GATA1 mutants, while retinoblastoma protein (Rb)-binding motif LXCXE
located around the Met84 is commonly deleted in GATA1-S and the ID-type GATA1 mutants
(Figure 3B). Because binding potential with the Rb protein is important for the GATA1
functions of controlling cell proliferation and promoting erythroid differentiation [52], loss of
the interaction with Rb protein may contribute, at least in part, to the GATA1 dysfunction
leading to the pathological process of TAM.
Figure 3. Rb-binding motif is commonly deleted in GATA1-S and the ID-type GATA1 mutants. A: domain structure
of GATA1. Of note is that a pRb-binding motif LxCxE (aa 81-85) is commonly in wild-type GATA1. B: when the pRb-
binding motif is eliminated in the GATA1-S and ID-type GATA1, the loss-of-function of the LxCxE motif appears to
contribute to the TAM genesis.
5. Leukemogenesis caused by GATA1 deficiency
GATA1/Gata1 gene is located on the X chromosome in humans and mice. Hemizygous male
mice with the GATA1-null germline mutation die in utero due to insufficient primitive
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erythropoiesis [53]. CFU-Meg (colony-forming unit-megakaryocyte) is significantly reduced
in the yolk sac of Gata1-null embryos, indicating that GATA1 is indispensable for the primitive
erythropoiesis and megakaryopoiesis. Independently, the GATA1-knockdown allele has also
been constructed by inserting a neomycin resistance cassette just upstream from the first exon
[54]. In this strain of mice, the strong promoter activity within the neomycin cassette directly
interferes with the expression of the Gata1 gene to approximately 5% of the wild-type level [54].
Hemizygous Gata1-knockdown mice also die in utero, showing a similar phenotype to the Gata1-
null mice. These results indicate that 5% of the GATA1 level cannot support primitive eryth‐
ropoiesis.
These two lines of Gata1-deficient mice have been maintained through heterozygous female
mice. In female mice carrying the Gata1 mutations, two types of hematopoietic progenitor cells
are developed depending on the X chromosome inactivation. Hematopoietic progenitors with
inactivated wild-type X chromosome and activated X chromosome with the Gata1 mutation
cannot differentiate into mature erythroid and megakaryocytic cells because of the defect in
GATA1 function. In contrast, hematopoietic progenitors in which wild-type X chromosome is
activated (and X chromosome with Gata1 mutation is inactivated) differentiate normally to
produce erythrocytes and platelets. Therefore, while Gata1-null and Gata1-knockdown hetero‐
zygous female embryos are anemic, these mice are born alive and grow normally.
However, interestingly, the female Gata1-knockdown mice frequently develop leukemia, while
female Gata1-null mice never develop leukemia and have a normal life expectancy [55].
Characterization of leukemia cells shows that the cells are positive for c-Kit (a stem cell factor
receptor) and CD71 (a transferrin receptor) antibodies but negative against the Ter119 (a
molecule associated with glycophorin A) antibody. Further analyses have revealed that the
leukemia is provoked by the residual 5% GATA1 in the immature erythroid progenitor cells
carrying the activated Gata1-knockdown allele. In contrast, the progenitor cells with the
activated Gata1-null allele never commit to leukemogenesis.
Because simple GATA1-deficiency causes a lethal embryonic phenotype, the roles of GATA1
in adult hematopoiesis are investigated using mice with conditional Gata1 gene ablation. Adult
Gata1-null mice produced by a conditional deletion of whole coding exons suffer from severe
anemia and thrombocytopenia [56]. These mice lack erythroid progenitors, showing a
phenotype resembling that of pure red cell aplasia. These results unequivocally indicate that
GATA1 is required for erythroid commitment and erythropoiesis in the early stage of hema‐
topoiesis. In addition, well-lobulated mature megakaryocytes that are positive for acetylcho‐
line esterase (AchE) staining are accumulated in the hematopoietic organs of conditional Gata1-
null mice, indicating that GATA1 is dispensable from the early stage of megakaryopoiesis and
megakaryocyte development to matured polyploid megakaryocytes [56].
An additional line of GATA1-deficient mice (referred to as Gata1ΔIE) has been produced by a
conditional deletion of the promoter/first exon of the Gata1 gene [57]. The conditional adult
Gata1ΔIE mice also suffer from anemia. However, unlike the conditional Gata1-null mice,
immature erythroid progenitors lacking terminal maturation potential to produce enucleated
erythrocytes are accumulated in the hematopoietic organs of conditional Gata1ΔIE mice. Also
in these conditional Gata1ΔIE mice, a small amount of aberrant Gata1 transcript is produced in
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the erythroid progenitors utilizing alternative first exons located in the first and the second
introns. These transcripts produce a small amount of GATA1-S, which supports the erythroid
commitment of hematopoietic progenitors, but the cells fail to complete terminal erythroid
maturation. In contrast, these aberrant transcripts are not produced in the megakaryocytes,
and the megakaryocytic phenotype of the conditional Gata1ΔIE mice is identical to that of the
conditional Gata1-null mice.
We have generated germline Gata1ΔIE mice by crossing the original flox mice with general Cre-
expressing mice. It is worth noting that heterozygous female mice with the germline Gata1ΔIE
allele are prone to developing erythroleukemia, similar to the female Gata1-knockdown mice
[58]. Thus, the impacts of changes in the expression level of GATA1 lead to the progression to
leukemia in the mice, while the consequences also affect the erythroid differentiation differ‐
entially.
6. Mouse models of TMD and DS-associated AMKL
A transgenic complementation rescue approach has been successfully applied for the investi‐
gation of GATA1 function in vivo. Expression of full-length GATA1 under the transcriptional
regulatory influences of Gata1 recapitulates the GATA1 function in vivo and rescues various
GATA1-deficient mice nicely from embryonic lethality [59]. Because transgene-derived
mutant GATA1 is exclusively expressed in the rescued mice, one can reasonably expect that
the phenotypes observed in the rescued mice occur due to the mutation.
Exploiting this rescue strategy, we have established transgenic lines of mice expressing
GATA1-S. Transgenic expression of GATA1-S rescues the GATA1-deficient males from
embryonic lethality [60]. Strikingly, immature megakaryocytes are accumulated in the fetal
livers of the rescued mice, but this phenotype disappears after birth [61], indicating that the
simple GATA1-S mutation provokes TMD-like phenotype in mice regardless of the presence
of disomy or trisomy of chromosome 16 (the equivalent of human chromosome 21). In a colony-
forming assay, progenitors with the GATA1-S mutation produced multiple progenies and
generated enormously large colonies, consisting of innumerable immature megakaryocytes
that were faintly positive for the AchE staining. In this assay, the number of CFU-Megs in the
rescued embryos was equivalent to that in the wild-type embryos. Thus, GATA1-S failed to
control proliferation and differentiation during the megakaryocyte differentiation process,
resulting in an uncontrolled growth of immature megakaryocytes. It should be noted that TAM
appears to be generated by single or a couple of hematopoietic progenitors acquiring the
GATA1-S mutation, whereas in the rescued mice, all progenitors express GATA1-S. These
observations suggest that the condition provided by trisomy 21 may lead to the onset of TAM
by exploiting two pathways: one increases the frequency of GATA1-S mutation, while the other
activates cellular mechanisms that magnify the impacts of the GATA1-S mutation.
One of the strong advantages of the transgenic complementation rescue assay is that levels of
transgene-derived GATA1-S can be controlled. Because the expression levels of transgene-
derived transcript vary between transgenic mouse lines depending on the integrated positions
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and/or copy numbers of the transgene, transgenic mouse lines expressing high-level GATA1-
S and low-level GATA1-S have been used for the rescue analyses. The mice expressing high
levels of GATA1-S never develop leukemia, whereas mice expressing low levels of GATA1-S
are prone to developing leukemia. The leukemic cells have biphenotypic characteristics of
erythroid and megakaryocyte lineages, closely resembling the human DS-associated AMKL
(our unpublished observation). Thus, the expression levels of GATA1-S appear to be reflected
in the transformation process of TAM blasts to genuine leukemia, consistent with the case of
leukemogenesis in the erythroid progenitors of Gata1-knockdown mice caused by GATA1-
deficiency.
Mice expressing GATA1 lacking N-terminal 63 amino acids have been established by gene
targeting [62]. This line of mice showed transient hyper-proliferation of megakaryocytes in the
fetal livers during the early stage of development, whereas the phenotype of the megakaryo‐
cytes in the later embryonic stages was close to normal. Because this mutant GATA1 molecule
preserves the consensus Rb-binding motif, the effect of GATA1 mutation may be reduced.
Another line of mice has been established by second exon deletion (Gata1Δe2), and, consequent‐
ly, only GATA-S is expressed in the Gata1Δe2 mice [62]. This line of mice also shows transient
hyper-proliferation of megakaryocytes during the early embryonic stage, similar to the GATA1
mutants lacking N-terminal 63 amino acids. In addition, the megakaryocyte progenitors
derived from bone marrow of the adult Gata1Δe2 mice are hyper-proliferative and formed
significantly larger colonies than those in wild-type mice [7]. While the mechanism underlying
the difference in the phenotypes of the rescued mice (hyper-proliferation of megakaryocytic
progenitors until the perinatal stage [61]) and the Gata1Δe2 mice (hyper-proliferation of
megakaryocytic progenitors only in the early embryonic stages [62]) is unclear at present, these
data congruently support the contention that the GATA1-S mutation alone gives rise to the
hyper-proliferation of megakaryocytic progenitors in fetal mouse livers.
By crossing Gata1Δe2 mice with DS-model lines of mice, i.e., Tc1 and Ts1Rh, the contributions
of GATA1-S mutation in combination with the trisomy of chromosome 21 to the leukemogen‐
esis have been analyzed. The frequency of CFU-Megs in fetal livers is increased by the
combination of Gata1Δe2 and Tc1 mutations. However, this finding appears insufficient to
provoke the onset of leukemia [39]. Similarly, when Ts1Rh mice are mated with Gata1Δe2 mice,
the compound mice did not show more phenotypes compared to the Gata1Δe2 mutant mice in
adulthood, except for further enlargement of megakaryocyte colony sizes [43]. The Ts1Rh and
Gata1Δe2 compound mutant mice never develop leukemia. However, intriguingly, bone
marrow cells are prone to transformation into leukemic cells when MPLW515L are retrovirally
overexpressed in the compound mutant mouse cells [43]. MPLW515L is an activating mutation
of the thrombopoietin receptor, which is frequently found in patients with myeloproliferative
neoplasms [63]. Therefore, it seems plausible that the megakaryocyte progenitors carrying the
GATA1-S mutation become sensitive to the oncogenic mutation by the presence of trisomy 21.
Thus, GATA1-S mutation in combination with trisomy 21 seems to give rise to the high
transformation potential, which may be involved in the increased risk of leukemogenesis in
DS children.
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7. Conclusion
GATA1 is a lineage restricted transcription factor that is responsible for the hematopoiesis in
erythroid and megakaryocyte lineages. GATA1 dysfunction leads to two types of leukemias.
One type originates from the quantitative deficit of GATA1, which causes accumulation of
immature erythroblasts and finally triggers erythroleukemia in mice [55]. The other type
originates from the qualitative defect of GATA1 (TMD and DS-associated AMKL) [64]. In the
latter case, the GATA1-S mutation is provoked in high frequency, and the mutation contributes
to the pathogenesis of TMD and DS-associated AMKL [49]. This structural change causes the
accumulation of immature megakaryoblasts and finally triggers megakaryoblastic leukemia
in mice and humans. Mice carrying a single GATA1-S mutation develop a phenotype resem‐
bling TAM [61]. In addition, trisomy 21 alters the function of hematopoietic cells [25-27], and
in cooperation with GATA1-S, it leads to the pathogenesis of TMD and DS-associated AMKL.
We surmise that the mouse models discussed in this chapter will provide important insights
into the pathogenesis of TMD and DS-associated AMKL.
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